Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2017 - 2025)

Iovance Biotherapeutics has reported Other Non-Current Assets over the past 8 years, most recently at $8.2 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $8.2 million for Q4 2025, up 28.42% from a year ago — trailing twelve months through Dec 2025 was $8.2 million (up 28.42% YoY), and the annual figure for FY2025 was $8.2 million, up 28.42%.
  • Other Non-Current Assets for Q4 2025 was $8.2 million at Iovance Biotherapeutics, down from $9.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for IOVA hit a ceiling of $66.4 million in Q4 2023 and a floor of $282000.0 in Q3 2023.
  • Median Other Non-Current Assets over the past 3 years was $6.4 million (2023), compared with a mean of $11.0 million.
  • Peak annual rise in Other Non-Current Assets hit 28.42% in 2025, while the deepest fall reached 93.37% in 2025.
  • Iovance Biotherapeutics' Other Non-Current Assets stood at $66.4 million in 2023, then tumbled by 90.43% to $6.4 million in 2024, then increased by 28.42% to $8.2 million in 2025.
  • The last three reported values for Other Non-Current Assets were $8.2 million (Q4 2025), $9.3 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.